Deficiency of SPARC suppresses intestinal tumorigenesis in APCMin/+ mice

Background and aims: SPARC (secreted protein acidic, rich in cysteine) is a matricellular protein that has been found to be activated in a number of human cancers. More recently, it has been shown to be upregulated in human gastric and colorectal cancer. We therefore wished to address the functional importance of SPARC upregulation to intestinal tumorigenesis in vivo. Methods: SPARC upregulation was determined in intestinal adenomas of tumour-prone ApcMin/+ mice at both the RNA and the protein level. To determine the functional importance of SPARC for intestinal tumorigenesis we then intercrossed Sparc knockout mice with ApcMin/+ mice (n  =  20). Intestinal enterocyte migration was examined using bromodeoxyuridine labelling studies. Results: Levels of murine Sparc and several related proteins were upregulated in adenomas arising in ApcMin/+ mice. A deficiency of Sparc strongly suppressed adenoma formation in ApcMin/+ mice (p⩾0.0001). Importantly, a deficiency of Sparc also accelerated enterocyte migration (p  =  0.01), as perturbed slow epithelial migration may underpin adenoma formation in the intestine. Conclusions: These data implicate Sparc in both cell migration and tumour formation, and identify Sparc as a potential therapeutic target for colorectal cancer.

[1]  O. Sansom,et al.  Apc deficiency predisposes to renal carcinoma in the mouse , 2005, Oncogene.

[2]  T. Freeman,et al.  Expression profiling of murine intestinal adenomas reveals early deregulation of multiple matrix metalloproteinase (Mmp) genes , 2005, The Journal of pathology.

[3]  M. Reed,et al.  SPARC-thrombospondin-2-double-null Mice Exhibit Enhanced Cutaneous Wound Healing and Increased Fibrovascular Invasion of Subcutaneous Polyvinyl Alcohol Sponges , 2005, Journal of Histochemistry and Cytochemistry.

[4]  R. Mahmood,et al.  Colonic tumorigenesis in BubR1+/-ApcMin/+ compound mutant mice is linked to premature separation of sister chromatids and enhanced genomic instability. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  O. Sansom,et al.  PPARδ status and Apc-mediated tumourigenesis in the mouse intestine , 2004, Oncogene.

[6]  S Hsueh,et al.  Overexpression of SPARC gene in human gastric carcinoma and its clinic–pathologic significance , 2004, British Journal of Cancer.

[7]  G. Riggins,et al.  Identification of astrocytoma associated genes including cell surface markers , 2004, BMC Cancer.

[8]  E. Sage,et al.  SPARC and tumor growth: Where the seed meets the soil? , 2004, Journal of cellular biochemistry.

[9]  E Helene Sage,et al.  Enhanced growth of pancreatic tumors in SPARC-null mice is associated with decreased deposition of extracellular matrix and reduced tumor cell apoptosis. , 2004, Molecular cancer research : MCR.

[10]  M. Colombo,et al.  Leukocyte, Rather than Tumor-produced SPARC, Determines Stroma and Collagen Type IV Deposition in Mammary Carcinoma , 2003, The Journal of experimental medicine.

[11]  Ji Min Park,et al.  Differential SPARC mRNA expression in Barrett's oesophagus , 2003, British Journal of Cancer.

[12]  William P Schiemann,et al.  SPARC inhibits epithelial cell proliferation in part through stimulation of the transforming growth factor-beta-signaling system. , 2003, Molecular biology of the cell.

[13]  Hiroshi Sato,et al.  Testican 2 abrogates inhibition of membrane-type matrix metalloproteinases by other testican family proteins. , 2003, Cancer research.

[14]  R. Brekken,et al.  Enhanced growth of tumors in SPARC null mice is associated with changes in the ECM. , 2003, The Journal of clinical investigation.

[15]  J. Fenton,et al.  Membrane-type matrix metalloproteinases mediate curcumin-induced cell migration in non-tumorigenic colon epithelial cells differing in Apc genotype. , 2002, Carcinogenesis.

[16]  M. Monden,et al.  Construction of preferential cDNA microarray specialized for human colorectal carcinoma: molecular sketch of colorectal cancer. , 2001, Biochemical and biophysical research communications.

[17]  J. Murphy-Ullrich.  The de-adhesive activity of matricellular proteins: is intermediate cell adhesion an adaptive state? , 2001, The Journal of clinical investigation.

[18]  R. Kucherlapati,et al.  Genotype-phenotype correlation in murine Apc mutation: differences in enterocyte migration and response to sulindac. , 1999, Cancer research.

[19]  E. Sage,et al.  SPARC deficiency leads to early-onset cataractogenesis. , 1998, Investigative ophthalmology & visual science.

[20]  M. Bertagnolli,et al.  Aspirin prevents tumors in a murine model of familial adenomatous polyposis. , 1998, Surgery.

[21]  J. Sanes,et al.  Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age‐onset cataract formation and disruption of the lens , 1998, The EMBO journal.

[22]  Eric S. Lander,et al.  Secretory phospholipase Pla2g2a confers resistance to intestinal tumorigenesis , 1997, Nature Genetics.

[23]  B. Schäfer,et al.  Isolation of genes differentially expressed in human primary myoblasts and embryonal rhabdomyosarcoma , 1996, International journal of cancer.

[24]  Clarke Ar,et al.  Interaction between murine germline mutations in p53 and APC predisposes to pancreatic neoplasia but not to increased intestinal malignancy. , 1995 .

[25]  O. Sansom,et al.  PPARdelta status and Apc-mediated tumourigenesis in the mouse intestine. , 2004, Oncogene.